Professor Dr. Zhan received his undergraduate and graduate training in the fields of preventive medicine and epidemiology and statistics at the West China University of Medical Sciences in China from 1989 to 1999. He received his post-doctoral training in oncology and cancer proteomics for two years at the Cancer Research Institute of Human Medical University in China. In 2001, he went to University of Tennessee Health Science Center (UTHSC) in the USA, where he was a post-doctoral researcher and was focused on mass spectrometry and cancer proteomics. Then, in 2005 he was appointed as Assistant Professor of neurology at UTHSC. In 2006 he moved to Cleveland Clinic in the USA as a project scientist / staff, where he focused on studies of eye disease proteomics and biomarkers. He returned to UTHSC as Assistant Professor of neurology at the end of 2007, engaging in proteomics and biomarker studies of lung diseases and brain tumors, and initiating the studies of predictive, preventive, and personalized medicine (PPPM) in cancer. In 2010, he was promoted to Associate Professor of neurology, UTHSC. Currently, he is a Professor at Xiangya Hospital of Central South University in China, fellow of the Royal Society of Medicine (FRSM), the European EPMA National Representative in China, regular member of the American Association for the Advancement of Science (AAAS), European Cooperation of Science and Technology (e-COST) grant evaluator, Associate Editor of BMC Genomics, BMC Medical Genomics, EPMA Journal, and Frontiers in Endocrinology, and Executive Editor-in-Chief of Med One. He has published 118 peer-reviewed research articles, 16 book chapters, and 2 US patents. His current main research interests are focused on cancer proteomics and biomarkers studies, and the use of modern OMICS techniques and systems biology for PPPM in cancer, post-translational modifications, and on development and use of isotope-labeled 2DE-LC/MS for large-scale study of human proteoforms.